nanotech investing Ventyx Biosciences Announces Positive Preclinical Data for CNS-Penetrant NLRP3 Inhibitor VTX3232 Demonstrating Reversal of Obesity and Improvements in Cardiometabolic and Inflammatory Markers
nanotech investing Ventyx Biosciences Announces Appointment of Matthew Moore as Chief Operating Officer
nanotech investing Ventyx Biosciences Reports First Quarter 2024 Financial Results and Highlights Recent Corporate Progress
